HK inno.N announced on the 10th that it held a domestic co-promotion contract signing ceremony with Tanabe Pharma Korea for “Vadanem Tablets” (ingredient name: vadadustat), a new drug for the treatment of renal anemia (anemia caused by impaired kidney function).

Under this agreement, HK inno.N and Tanabe Pharma Korea will jointly conduct sales and marketing for Vadanem Tablets in Korea. Specifically, medical institutions with more than 100 beds will be jointly covered by the two companies, while institutions with 100 beds or fewer will be handled exclusively by HK inno.N. Through exclusive domestic distribution of Vadanem Tablets, HK inno.N plans to actively target the treatment segment for patients with chronic kidney disease.

The co-promotion signing ceremony was held at the Tanabe Pharma Korea office in Yeouido, Yeongdeungpo, Seoul. HK inno.N CEO Kwak Dal-won, Tanabe Pharma Korea CEO Lee Won-gyu, and other key officials attended to reaffirm their commitment to cooperation.

Vadanem Tablets is an oral therapy used to treat anemia in adult patients with chronic kidney disease who are on dialysis. It is a new drug belonging to the class of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors. It is available in two strengths, 150 mg and 300 mg, and is taken once daily. HK inno.N already has a portfolio of kidney disease-related products, including the dialysis-delaying agent Kremezin (spherical carbon adsorbent) and the injectable renal anemia treatment Epokine (EPO). With the addition of Vadanem Tablets, the company has further strengthened its portfolio.

HK inno.N CEO Kwak Dal-won said, “We expect that the kidney disease product portfolio built up so far and our robust sales infrastructure will create strong synergy for Vadanem Tablets sales,” adding, “Through close collaboration, we will contribute to improving the quality of life of domestic chronic kidney disease patients.”

Vadanem Tablets was developed by the U.S. pharmaceutical company Akebia Therapeutics. Japanese pharmaceutical company Tanabe Pharma holds the marketing rights for certain Asian countries, including Japan and Korea. In the United States, the drug was approved by the U.S. Food and Drug Administration (FDA) in 2024 under the product name Vafseo. Recognized for its efficacy and safety, it has been prescribed since January last year. In Korea, it received marketing approval in March 2023 and was recognized for reimbursement appropriateness in July last year, passing the Health Insurance Review and Assessment Service’s Subcommittee on Reimbursement Standards.

Popular News